Antipsychotic medication and tobacco use among outpatients with schizophrenia: a cross-sectional study

Hiranya Wijesundera,Varuni A De Silva,Raveen Hanwella

doi:10.1186/1744-859x-13-7

Hiranya Wijesundera, Varuni A De Silva + Show 1 more

Open Access

https://doi.org/10.1186/1744-859x-13-7

Copy DOI

Abstract

BackgroundMany studies have shown that the prevalence of smoking in schizophrenia is higher than in the general population. Biological, psychological and social factors influence smoking in patients with schizophrenia.MethodsThe study was carried out in psychiatry outpatient clinics in a tertiary care hospital in Sri Lanka. Every third patient was selected using systematic sampling from patients diagnosed with schizophrenia according to ICD-10 clinical criteria. Smoking behaviours were assessed using self-reports. Severity of illness was assessed using Brief Psychiatric Rating Scale (BPRS). Fagerstrom Test for Nicotine Dependence assessed level of dependence. Readiness to Change Questionnaire assessed motivation to change smoking behaviour.ResultsThe sample consisted of 306 patients with schizophrenia. Mean age was 38.93 years (SD 10.98). There were 148 males (48.4%). Mean duration of illness was 12.63 years (SD 8.38). Current medication was oral atypical antipsychotics 103, clozapine 136, oral typicals 29 and depot typicals 38. Prevalence of tobacco use among males was 30.41% (95% CI 22.91 to 37.90) and among females 1.90% (95% CI -0.25 to 4.05). Prevalence of current smoking among males was 20.27% (95% CI 13.72 to 26.82). None of the females smoked. Prevalence of smokeless tobacco use among males was 10.14 (95% CI 5.22 to 15.05) and among females 1.90 (95% CI -0.03 to 4.05). When patients treated with clozapine were excluded from the analysis, prevalence of tobacco use was 41.6% among males and 3.2% among females and prevalence of smoking was 29.9% among males. Prevalence of tobacco use was lowest in patients treated with clozapine 18.31 (95% CI 9.09 to 27.53) and highest in those treated with depot antipsychotics 47.83 (95% CI 25.74 to 69.91).ConclusionsPrevalence of smoking was less than in many countries. This is influenced by prevalence in the general population and low affordability. Risk of tobacco use was significantly less among patients treated with clozapine.

Highlights

Many studies have shown that the prevalence of smoking in schizophrenia is higher than in the general population
Eight patients on either risperidone or olanzapine were treated with an oral typical antipsychotic
Polypharmacy was commonest among patients treated with a depot antipsychotic with 8 (19.5%) treated with risperidone or olanzapine and 10 (24.4%) treated with an oral typical antipsychotic

Summary

Introduction

Many studies have shown that the prevalence of smoking in schizophrenia is higher than in the general population [2,3,4,5,6]. Smoking has health implications for patients with schizophrenia because it increases the risk of cardiovascular disease and malignancies and causes overall poor physical health and premature death. The prevalence of smoking in different countries ranges from 14% to 88%, with majority reporting prevalence between 40% and 70%. The dorsal anterior cingulate (dACC) functional circuits are key paths for increased risk of smoking co-morbidity in schizophrenia [10]

Methods

Results

Discussion

Conclusion